Arvinas Inc. logo

Arvinas (ARVN) stock

ARVN · Arvinas Inc. · NASDAQ

Website
Market cap
$423.0M
EPS (TTM)
-$0.10
Shares out
65.5M

What is the latest news on ARVN stock?

PRago
GeneDx Announces Leadership Transition

Everett Cunningham, veteran diagnostics and commercial leader, appointed Chief Executive Officer to lead next phase of growthKatherine Stueland announces her departure from the company after successful transformation of GeneDxGeneDx (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that its Board of Directors has appointed Everett Cunningham as Chief Executive Officer and a member of the Board, effective on or before December 15, 2026. Mr. Cunningham succeeds Katherine Stueland, who has announced that she will step down as Chief Executive Officer and as a member of the Board when Mr. Cunningham joins GeneDx. Ms. Stuelan

All ARVN news

When does Arvinas report earnings?

Arvinas last reported on Nov 3, 2026, the date it announced on Oct 27, 2026. Before that it reported on Aug 4, 2026 and May 12, 2026. On that schedule the next report would come around early February 2027, with the date usually announced about 1 week ahead.

ARVN earnings history

Who owns the most ARVN stock?

BlackRock, Inc. was the largest reported holder of ARVN at the end of Q2 2026, with 7,609,123 shares worth $63.2 million. Next came Vanguard Portfolio Management LLC ($34.3 million) and D. E. Shaw & Co., Inc. ($29.0 million). In all, 201 institutions reported $474.2 million of ARVN in their 13F filings.

All ARVN fund holders

Are insiders buying or selling ARVN?

Insiders are selling. In the last 90 days 1 insider sold $1K of ARVN in trades reported on Form 4. The latest: David K Loomis sold $1K, reported on Nov 9, 2026.

ARVN insider trades

Financial highlights

Full financials
Revenue, TTM
$275.30M
Revenue growth
-11.8%
Net income, TTM
-$9.50M
Net margin
-3.5%
Free cash flow, TTM
-$160.20M
Cash
$88.00M

For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.

Latest news

25 items

Hiring

Nov 22, 2026

Arvinas Inc. lists 3 open roles on its careers site as of Nov 22, 2026, the most in Technical Operations (2). 2 of them were posted in the last week.

Open roles
3
Posted this week
2

By team

  • Technical Operations
    2
  • Medicinal Chemistry
    1

By location

  • Remote, Hybrid, New Haven - CT2
  • New Haven - CT1

Counted daily from Arvinas Inc.'s careers site.

ARVN rankings

News · 26 weeks43+200%
2026-05-31: 22026-06-07: 02026-06-14: 22026-06-21: 102026-06-28: 02026-07-05: 12026-07-12: 02026-07-19: 02026-07-26: 12026-08-02: 52026-08-09: 12026-08-16: 02026-08-23: 02026-08-30: 32026-09-06: 12026-09-13: 02026-09-20: 12026-09-27: 42026-10-04: 12026-10-11: 02026-10-18: 02026-10-25: 22026-11-01: 52026-11-08: 22026-11-15: 22026-11-22: 0
2026-05-312026-11-22
Mix2190d
  • Other9(43%)
  • SEC Filings8(38%)
  • Earnings2(10%)
  • Insider1(5%)
  • Leadership1(5%)
Activity · 52 weeks10259 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news

Arvinas Inc. (ARVN) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 11 wire items for ARVN, including 4 SEC filings, 3 press releases and news items and 2 earnings updates. The most recent was published Nov 18, 2026.

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Bayer AG, and Insilico Medicine, Inc. Arvinas, Inc. was incorporated in 2013 and is based in New Haven, Connecticut.

ARVN FAQ

11 questions
  • What does Arvinas Inc. do?
    Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The...
  • What is ARVN revenue?
    Arvinas Inc. (ARVN) reported $275.30M of revenue for the twelve months ended Sep 30, 2026. That is down 11.8% from the year before. Revenue for fiscal 2025 was $262.60M.
  • Is ARVN profitable?
    No. Arvinas Inc. reported a net loss of $9.50M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does ARVN have?
    Arvinas Inc. reported $88.00M in cash and cash equivalents and $400.0K of debt on its most recent balance sheet in SEC filings.
  • Is Arvinas Inc. (ARVN) hiring?
    Arvinas Inc. lists 3 open roles on its careers site as of Nov 22, 2026, the most in Technical Operations (2). 2 of them were posted in the last week. The most openings are in Remote, Hybrid, New Haven - CT and New Haven - CT.
  • Where does ARVN stock trade?
    Arvinas Inc. (ARVN) is listed on NASDAQ.
  • What sector and industry is ARVN in?
    Arvinas Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
  • When did Arvinas Inc. go public?
    Arvinas Inc. (ARVN) completed its IPO in 2018.
  • What are analysts saying about ARVN?
    Across the last 8 analyst actions on Arvinas Inc., there was 1 upgrade and 6 downgrades. The most recent action was from Wells Fargo: Equal Weight on 2026-08-04. Recent price targets range from $6.00 to $16.00.
  • What companies are similar to ARVN?
    Notable peers in the same industry include NRIX (Nurix Therapeutics Inc.), GLUE (Monte Rosa Therapeutics Inc.), CCCC (C4 Therapeutics Inc.), KYMR (Kymera Therapeutics Inc.). Compare ARVN side-by-side with any of them on Quantisnow.
  • How can I track ARVN on Quantisnow?
    Quantisnow aggregates Arvinas Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ARVN to receive live email and push alerts on every new disclosure.

Is something on this page wrong, or out of date? Request a change